Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq™) and IG-004 (TOCOSOL® paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind".

IG-001 (Cynviloq™) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC ind
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015  Research and Benchmarking firm, ... Medical Affairs Roundtable on Thursday, May ... virtual roundtable to discuss "Medical Affairs, Role in ... Practices, Medical Affairs Consortium provides Medical Affairs leaders ... key challenges they face. The consortium has developed ...
(Date:5/22/2015)... /CNW/ - The Taskforce representing Canada,s ... hard work that the Minister and Health Canada have put ... recognizes the needs of the thalidomide survivors, and more than ... tax free, with annual adjustments for inflation. Certain ... of $100,000 based on the severity of their disability, tax ...
(Date:5/22/2015)... , May 22, 2015  Amgen (NASDAQ: ... has commenced termination of its participation in ... AstraZeneca (LON:AZN, STO:AZN and NYSE: AZN ... in development for patients with moderate-to-severe plaque ... decision was based on events of suicidal ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... , ATLANTA, Dec. 16 Medlytix, a national healthcare ... half-billion dollar milestone - the total amount of money that ... than a half-million patients nationwide by doing a better job ... years. , "We,re proud that each of these hospitals enhanced ...
... , SOMERVILLE, N.J., Dec. 16 Ethicon, Inc., a ... a worldwide leader in surgical care, and Acclarent, Inc., a ... commercializing devices that address conditions affecting the ear, nose and ... will acquire Acclarent in an all-cash transaction for approximately $785 ...
Cached Medicine Technology:Healthcare Scoring System Allows Hospitals To Increase Charity Care 2Healthcare Scoring System Allows Hospitals To Increase Charity Care 3Healthcare Scoring System Allows Hospitals To Increase Charity Care 4Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4
(Date:5/23/2015)... 23, 2015 Dr. David Benvenuti, an experienced ... posted a new article to his website that ... Dr Benvenuti explained in the fascinating blog, he has ... their earlobes. , Known as “gauging,” the technique involves placing ... Dr. Benvenuti said will eventually stretch the holes out to ...
(Date:5/23/2015)... With the implementation of the Affordable ... increasingly difficult to provide their employees with a viable ... insurance for employees stand to face strict penalties. Never ... part of a business’s success or failure. In an ... USA Doctors has created a varying level of less ...
(Date:5/23/2015)... New York, NY (PRWEB) May 23, 2015 ... (CareFirst) announced that, “the company has been the ... discovered as a part of the company’s ongoing Information ... cyberattacks on health insurers.” , The most notable ... this year when Anthem Inc., the nation’s second largest ...
(Date:5/23/2015)... CO (PRWEB) May 23, 2015 On May ... in MuckFest. The event was a 5k mud obstacle run ... more than 2 million people worldwide, and the reason we ... community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred ... Multiple Sclerosis Society.” , The event was not only attended ...
(Date:5/23/2015)... 23, 2015 Manufacturers are now required to ... (HSPF) of 8.2. Experts in the field agree that the ... , The HSPF score is what miles per gallon is ... the unit. Although the minimum HSPF score has been raised ... an HSPF score north of 12. Indeed, the regulation was ...
Breaking Medicine News(10 mins):Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2
... cancer (CRC) is the third leading cause of cancer ... of people who need CRC screening receive it. The ... patients about the importance of screening and to encourage ... CRC. Recognizing that those without insurance have ...
... preparation (ICCBco) in the treatment of lung lesions ... experimental animal model, a research group in China ... pathological changes and pathological effect mechanism of expression ... of portal hypertensive rabbits with schistosomiasis. ...
... risk, but elderly women are too, study finds , THURSDAY, ... cause of shoulder dislocation, and young males have the highest ... shows. , Researchers studied 8,940 shoulder dislocations treated at 100 ... 2006 and found that the overall incidence rate was 23.9 ...
... ... MD, MPH, to determine whether they are allergic to penicillin. In years past, this was ... new product called Pre-Pen in his office, and is available for testing. , ... (PRWEB) March 4, 2010 -- Patients with ...
... ... ... , ... , , ...
... ... ... ... ...
Cached Medicine News:Health News:Physicians come together on National Colorectal Cancer Awareness and Screening Day 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Shoulder Dislocations a Sports Hazard 2Health News:New Allergy Testing Available for Patients Allergic to Penicillin: Determining the Presence of Penicillin Allergy is Essential to Patient Care 2Health News:Cymetrix Board Member Recognized for Enhancing the Growth and Operations of the Companies He Advises 2Health News:Cymetrix Board Member Recognized for Enhancing the Growth and Operations of the Companies He Advises 3Health News:Cymetrix Board Member Recognized for Enhancing the Growth and Operations of the Companies He Advises 4Health News:Thyroid Disease: The Hidden Epidemic 2Health News:Thyroid Disease: The Hidden Epidemic 3Health News:Thyroid Disease: The Hidden Epidemic 4
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
... a national reference laboratory and a ... offers an extensive test menu of ... in clinical and anatomic pathology. Owned ... Laboratories clients include university teaching hospitals ...
Sharp tipped scissors angled 135 from the shaft with a horizontal cutting action. For cutting in the plane parallel to the retina and cutting membranes adherent to the retinal surface (delamination)....
Disposable Microscissors: Horizontal, Straight...
Medicine Products: